Certifications, Authorizations, Stock Updates, and Upcoming Conferences - Analyst Notes on Edwards Lifesciences, Alkermes, ResMed, Auxilium, and Teleflex

NEW YORK, April 10, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Edwards Lifesciences Corp (NYSE: EW), Alkermes Plc (NASDAQ: ALKS), ResMed Inc. (NYSE: RMD), Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), and Teleflex Incorporated (NYSE: TFX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

Edwards Lifesciences Corp Analyst Notes 

On April 4, 2014, Edwards Lifesciences Corp (Edwards Lifesciences) announced that its advanced EDWARDS INTUITY Elite valve system has received CE Mark. According to the Company, this next-generation valve system combines a unique balloon-expandable frame with Edwards' proven pericardial PERIMOUNT platform, and has design improvements intended to improve ease of use, including a flexible and lower profile delivery system that is designed to facilitate access and visibility through smaller incisions. Prof. Michael Borger, M.D. Ph.D., Associate Director of the Department of Cardiac Surgery at the Leipzig Heart Center in Germany, commented, "We're encouraged by the introduction of heart valve technologies that are developed to facilitate a minimally invasive approach for the improved treatment of patients with aortic valve disease. Our experience with the EDWARDS INTUITY platform has shown the ability to implant the valve through smaller incisions, with significantly reduced cross-clamp time and improved hemodynamics. This less-invasive, more efficient surgical approach should benefit patients during and after their procedure." The full analyst notes on Edwards Lifesciences Corp are available to download free of charge at:

http://www.AnalystsReview.com/04102014/EW/report.pdf

Alkermes Plc Analyst Notes 

On April 7, 2014, Alkermes Plc's (Alkermes) stock slipped 1.04% to close at $41.10. Over the past three months of trading, Alkermes' stock gained 1.58% while the Nasdaq Composite declined 1.77% during the same period. The full analyst notes on Alkermes Plc are available to download free of charge at:

http://www.AnalystsReview.com/04102014/ALKS/report.pdf

ResMed Inc. Analyst Notes 

On March 25, 2014, ResMed Inc. (ResMed) announced that it has scheduled the release of its Q3 FY 2014 and 9M FY 2014 results (period ended March 31, 2014) on Wednesday, April 23, 2014, after 1:00 p.m. PT. The Company added that a conference call will follow at 1:30 p.m. PT on the same day to review the results, market trends, and future outlook. ResMed stated that the call can be accessed at the Company website, where an archive will be made available for 2 weeks after the call. The full analyst notes on ResMed Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04102014/RMD/report.pdf

Auxilium Pharmaceuticals, Inc. Analyst Notes 

On April 7, 2014, Auxilium Pharmaceuticals, Inc. (Auxilium), along with Swedish Orphan Biovitrum AB (Sobi), announced that Sobi is now the Market Authorisation Holder (MAH) for Xiapex® (collagenase clostridium histolyticum), in 28 EU member countries, Norway, and Iceland on April 3, 2014. According to the Company, Sobi, if it chooses to do so, may now file for market authorization for Xiapex for the treatment of Peyronie's disease and work is ongoing for that filing in the EU. Auxilium stated that Sobi holds the exclusive rights to commercialise Xiapex for the Dupuytren's contracture and Peyronie's disease indications, in these countries subject to applicable regulatory approvals. Auxilium informed that Xiapex/ XIAFLEX® is a first-in-class biologic approved in the US, EU, Canada and Australia for the treatment of adult patients of Dupuytren's contracture - a progressive condition affecting the hand -with a palpable cord and in the US for the treatment of adult men with Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy. The full analyst notes on Auxilium Pharmaceuticals, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04102014/AUXL/report.pdf

Teleflex Incorporated Analyst Notes 

On April 7, 2014, shares in Teleflex Incorporated (Teleflex) dropped 1.12% or by 1.19 points to close trading at $105.47. Shares in Teleflex increased over the past six months of trading by 28.08%, in comparison with the Nasdaq Composite which gained 8.21% during the same period. The full analyst notes on Teleflex Incorporated are available to download free of charge at:

http://www.AnalystsReview.com/04102014/TFX/report.pdf

About Analysts Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

=============

EDITOR NOTES: 

• This is not company news. We are an independent source and our views do not reflect the companies mentioned.
• Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
• This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
• If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
• For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
• Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.

COMPLIANCE PROCEDURE 

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE 

Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED 

Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

http://www.AnalystsReview.com/

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED